• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Societal CDMO Inc.

    4/8/24 11:28:26 AM ET
    $SCTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCTL alert in real time by email
    S-8 POS 1 d797397ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on April 8, 2024

    No. 333-278191

    No. 333-278189

    No. 333-270192

    No. 333-270189

    No. 333-263179

    No. 333-263180

    No. 333-253574

    No. 333-253573

    No. 333-236875

    No. 333-229737

    No. 333-229736

    No. 333-224870

    No. 333-223437

    No. 333-223436

    No. 333-216581

    No. 333-216579

    No. 333-208750

    No. 333-208749

    No. 333-206309

    No. 333-194730

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to:

    FORM S-8 REGISTRATION STATEMENT No. 333-278191

    FORM S-8 REGISTRATION STATEMENT No. 333-278189

    FORM S-8 REGISTRATION STATEMENT No. 333-270192

    FORM S-8 REGISTRATION STATEMENT No. 333-270189

    FORM S-8 REGISTRATION STATEMENT No. 333-263179

    FORM S-8 REGISTRATION STATEMENT No. 333-263180

    FORM S-8 REGISTRATION STATEMENT No. 333-253574

    FORM S-8 REGISTRATION STATEMENT No. 333-253573

    FORM S-8 REGISTRATION STATEMENT No. 333-236875

    FORM S-8 REGISTRATION STATEMENT No. 333-229737

    FORM S-8 REGISTRATION STATEMENT No. 333-229736

    FORM S-8 REGISTRATION STATEMENT No. 333-224870

    FORM S-8 REGISTRATION STATEMENT No. 333-223437

    FORM S-8 REGISTRATION STATEMENT No. 333-223436

    FORM S-8 REGISTRATION STATEMENT No. 333-216581

    FORM S-8 REGISTRATION STATEMENT No. 333-216579

    FORM S-8 REGISTRATION STATEMENT No. 333-208750

    FORM S-8 REGISTRATION STATEMENT No. 333-208749

    FORM S-8 REGISTRATION STATEMENT No. 333-206309

    FORM S-8 REGISTRATION STATEMENT No. 333-194730

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SOCIETAL CDMO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Pennsylvania   26-1523233

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    1 E. Uwchlan Ave, Suite 112

    Exton, Pennsylvania

      19341
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    RECRO PHARMA, INC. 2018 AMENDED AND RESTATED EQUITY INCENTIVE PLAN

    RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN

    RECRO PHARMA, INC. 2008 STOCK OPTION PLAN

    NON-QUALIFIED STOCK OPTION INDUCEMENT AWARDS

    RESTRICTED STOCK UNIT INDUCEMENT AWARDS

    (Full titles of the plans)

    Jeffrey Edwards

    President

    Societal CDMO, Inc.

    1 E. Uwchlan Ave, Suite 112

    Exton, Pennsylvania 19341

    (Name and address of agent for service)

    (770) 534-8239

    (Telephone number, including area code, of agent for service)

    Copy To:

    Gerald F. Roach

    Byron B. Kirkland

    Heyward D. Armstrong

    Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.

    150 Fayetteville Street, Suite 2300

    Raleigh, North Carolina 27609

    Telephone: (919) 821-6668

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Post-Effective Amendment No. 1 relates to the following Registration Statements of Societal CDMO, Inc. (the “Company”) on Form S-8 (collectively, the “Registration Statements”):

     

      •  

    Registration Statement No. 333-278191, registering 5,239,934 shares of common stock of the Company, par value $0.01 per share (“Shares”), issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Securities and Exchange Commission (the “Commission”) on March 22, 2024;

     

      •  

    Registration Statement No. 333-278189, registering 265,830 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees, filed with the Commission on March 22, 2024;

     

      •  

    Registration Statement No. 333-270192, registering 2,835,032 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on March 1, 2023;

     

      •  

    Registration Statement No. 333-270189, registering 397,010 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees, filed with the Commission on March 1, 2023;

     

      •  

    Registration Statement No. 333-263179, registering (i) 398,743 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees and (ii) 15,000 Shares issuable upon exercise of the restricted stock unit awards granted by the Company to certain employees, filed with the Commission on March 1, 2022;

     

      •  

    Registration Statement No. 333-263180, registering 2,330,726 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on March 1, 2022;

     

      •  

    Registration Statement No. 333-253574, registering 1,212,231 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on February 26, 2021;

     

      •  

    Registration Statement No. 333-253573, registering (i) 194,175 Shares issuable upon exercise of the non-qualified stock option award granted by the Company to David Enloe and (ii) 217,822 Shares issuable upon exercise of the restricted stock unit award granted by the Company to David Enloe, filed with the Commission on February 26, 2021;

     

      •  

    Registration Statement No. 333-236875, registering 1,161,693 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on March 4, 2020;

     

      •  

    Registration Statement No. 333-229737, registering (i) 73,250 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees and (ii) 5,000 Shares issuable upon exercise of the restricted stock unit awards granted by the Company to certain employees, filed with the Commission on February 19, 2019;

     

      •  

    Registration Statement No. 333-229736, registering 1,082,972 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on February 19, 2019;

     

      •  

    Registration Statement No. 333-224870, registering 3,000,000 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on May 11, 2018;

     

      •  

    Registration Statement No. 333-223437, registering 956,341 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on March 5, 2018;

     

      •  

    Registration Statement No. 333-223436, registering (i) 542,750 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees and (ii) 42,000 Shares issuable upon exercise of the restricted stock unit awards granted by the Company to certain employees, filed with the Commission on March 5, 2018;

     

      •  

    Registration Statement No. 333-216581, registering 231,000 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees, filed with the Commission on March 9, 2017;

     

      •  

    Registration Statement No. 333-216579, registering 619,181 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on March 9, 2017;

     

      •  

    Registration Statement No. 333-208750, registering 133,000 Shares issuable upon exercise of the non-qualified stock option awards granted by the Company to certain employees, filed with the Commission on December 23, 2015;


      •  

    Registration Statement No. 333-208749, registering 461,215 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on December 23, 2015;

     

      •  

    Registration Statement No. 333-206309, registering 1,400,000 Shares issuable pursuant to the Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan, filed with the Commission on August 12, 2015; and

     

      •  

    Registration Statement No. 333-194730, registering (i) 444,000 Shares issuable pursuant to the Recro Pharma, Inc. 2008 Stock Option Plan and (ii) 600,000 Shares issuable pursuant to the Recro Pharma, Inc. 2013 Equity Incentive Plan, filed with the Commission on March 21, 2014.

    On February 28, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CoreRx, Inc., a Florida corporation (“Parent”) and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned subsidiary of Parent (“Purchaser”). Pursuant to the Merger Agreement, on April 8, 2024, Purchaser merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

    In connection with the Merger, the offerings of securities pursuant to the Registration Statements have been terminated. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered pursuant to the Registration Statements which remain unsold at the termination of the offerings, the Company hereby terminates the effectiveness of each Registration Statement and removes from registration all Shares registered under the Registration Statements that remain unsold as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to this Post-Effective Amendment No. 1 to the Registration Statements, there will be no remaining securities registered by the Company pursuant to the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Exton, Commonwealth of Pennsylvania, on April 8, 2024.

     

    SOCIETAL CDMO, INC.
    By:   /s/ Jeffrey Edwards
    Name:   Jeffrey Edwards
    Title:   President

    No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $SCTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCTL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

      Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. ("CoreRx") under which CoreR

      2/28/24 4:29:04 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Societal CDMO Announces Appointment of Matt Arens to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company's board of directors. Mr. Arens has more than 25 years of experience as a successful investment professional identifying innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios. Mr. Arens currently serves as chief executive officer and senior po

      8/23/23 4:04:35 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Societal CDMO Appoints Elena Cant to Board of Directors

      SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Elena Cant to the company's board of directors. Ms. Cant has more than 20 years of diverse business experience ranging across various functions including corporate development, business operations and strategy, marketing, commercial, manufacturing, and research and development. She has an impressive track record of establishing and growing functional groups,

      9/8/22 7:00:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Financials

    Live finance-specific insights

    See more
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20

      4/8/24 4:05:23 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

      CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an

      4/8/24 10:10:00 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

      Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include

      11/14/22 6:45:00 AM ET
      $CING
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Societal CDMO Inc.

      15-12G - Societal CDMO, Inc. (0001588972) (Filer)

      4/18/24 3:27:56 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:06 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Societal CDMO Inc.

      EFFECT - Societal CDMO, Inc. (0001588972) (Filer)

      4/12/24 12:15:10 AM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Societal CDMO Inc. (Amendment)

      SC 13D/A - Societal CDMO, Inc. (0001588972) (Subject)

      4/9/24 4:15:44 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Societal CDMO Inc.

      SC 13G - Societal CDMO, Inc. (0001588972) (Subject)

      4/1/24 5:03:18 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Societal CDMO Inc.

      SC 13D - Societal CDMO, Inc. (0001588972) (Subject)

      3/6/24 5:11:25 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arens Mathew Paul closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:37:26 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Weisman Wayne returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:36:07 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reasons Bryan M. returned $80,982 worth of shares to the company (73,620 units at $1.10), closing all direct ownership in the company (SEC Form 4)

      4 - Societal CDMO, Inc. (0001588972) (Issuer)

      4/8/24 9:34:32 PM ET
      $SCTL
      Biotechnology: Pharmaceutical Preparations
      Health Care